Market brief — August 8, 2026

Friday, markets closed with the CAC 40 at 8,714.93, up 0.17%, the S&P 500 at 7,757.64, up 0.62%, the Nasdaq at 26,690.62, up 1.30%, the DAX at 26,319.45, up 0.69%, and the Euro Stoxx 50 at 6,523.86, up 0.33%, a clear rebound versus the previous session’s softer tone and one that looks more like a relief/risk-reengagement move than a fresh macro repricing. The dominant driver into the weekend is still rate-sensitive equity leadership rather than a broad de-risking shock: U.S. and European indices advanced together, with growth and duration-sensitive segments doing the heavy lifting, while Asian risk indicators were already firmer overnight, including GIFT Nifty up 0.32% and U.S. tech futures up 1.28%, confirming that investors are leaning back into cyclically positive, liquidity-sensitive exposure rather than fading risk altogether^[4][8][15].

That setup matters because the cross-asset tape is not showing stress consistent with an immediate macro break. The move higher in equities alongside firmer tech futures suggests systematic and discretionary buyers were willing to add exposure after the prior session’s hesitation, with the strongest participation likely in U.S. large-cap growth and rate proxies. The more important divergence is that the rally broadened beyond pure megacap technology into industrial and healthcare names, which argues against a narrow squeeze alone. Overnight Asia did not produce a decisive risk-off spillover; instead, the focus appears to be on whether the market can sustain a softer real-rates narrative into next week, versus re-pricing back toward tighter financial conditions if yields or commodities reassert themselves^[4][8][13]. In that context, commodities and rates remain the key confirmation variables: if long-end yields stay contained and oil does not re-accelerate, this rebound can extend; if either breaks higher, the current tone is more likely to fade into sector rotation.

The Cash Scanner confirms that leadership is not just macro-beta, but a mix of momentum, breakouts, and selective idiosyncratic rerating. Tandem Diabetes Care (TNDM) scored 38 with a +19.1% gap, a 20-day breakout, stronger volume, and rising Vortex signals; Halozyme Therapeutics (HALO) scored 38 with a +20.2% gap, breakout confirmation, heavy volume, and ADX 36; and Five9 (FIVN) scored 38 with a +19.8% gap, another 20-day breakout and volume expansion. That clustering in healthcare and software says the tape is rewarding earnings-sensitive gap moves more than pure factor exposure, while First Solar (FSLR) at score 40 with a +2.4% gap and ADX 33 shows renewable/industrial-tech strength is still active. The presence of Baxter International (BAX), 3M (MMM), and Fastenal (FAST) adds a cyclical-industrial layer, so this is not a one-sector chase; it is a quality-growth plus selective industrial repair basket, not an all-in risk-on melt-up.

Over the next 1–5 sessions, the dominant narrative is whether this is the start of a more durable rotation into duration-sensitive growth and select industrials, or just a weekend positioning reset after a choppy prior session. Consensus appears to expect a benign continuation unless rates or oil reprice higher, but that leaves upside in equities partially “already assumed” while underestimating how quickly sector leadership can rotate if long-end yields back up. A credible contrarian scenario is that the market overreads the weekend’s calmer tone and quickly unwinds Monday if macro data or central-bank commentary re-anchors hawkish expectations.

The most important upcoming catalysts are the next U.S. inflation-related releases and any central-bank communication that shifts the path for real yields, because those are the cleanest drivers of Nasdaq leadership and the sustainability of the current breadth improvement. In Europe, any fresh signal on growth or energy costs could hit the DAX and CAC via cyclicals and rate expectations. In Asia, overnight commodity and index tone will matter because they can either validate the current rebound or force a risk reset before the U.S. open.

The main risks are a renewed jump in long-end sovereign yields, an oil spike that reintroduces inflation anxiety, and an earnings/guidance miss from a large growth or healthcare bellwether that undermines the scanner’s breakout signals. A less obvious risk is that the current rally is too dependent on short covering and systematic re-risking, making it vulnerable if volatility stops compressing. If the VIX lifts while the Nasdaq loses momentum, that would be the first sign the rebound is losing sponsorship.

If the S&P 500 holds above Friday’s close and the Nasdaq maintains relative strength into the new week, the current regime favors continuation in names like Five9, Halozyme, and Tandem Diabetes Care; if not, those same breakout leaders are the first place to watch for failed follow-through. If U.S. tech futures remain firm and European indices track higher at the open, the market is telling you the rate narrative is still constructive; if oil or yields reverse that signal, then 3M, Fastenal, and First Solar become the better barometers of whether the rotation is real or just tactical. If cash equities stay resilient while credit remains calm, this is a buy-the-dip tape; if not, the current move should be treated as a short-lived positioning rebound rather than a regime shift.

Bonne journée aux p&l makers.